Media Newsroom of

qr pharma

1055 Westlakes Drive
Berwyn, PA 19312
Phone: 610 727 3710

QR is currently developing Posiphen as a disease-modifying drug for acute as well as chronic neurodegeneration. Posiphen is in phase II for Alzheimer's disease.

QR Pharma Announces New Scientific Advisory Board

QR Pharma, Inc., a privately held Phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer's, Parkinson's and other neurodegenerative diseases, today announced the appointment of four world-class key opinion leaders to its Scientific Advisory Board (SAB). These…


Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or Signup using Email

Already have an account ? Login

Reset Password

Already have an account ? Login